November 19th 2023
A study conducted by the American Cancer Society found patients who were Black received worse care for colorectal cancer treatment, with health insurance is the leading cause of racial disparities.
Medical Crossfire®: Multidisciplinary Strategies to Leverage Clinical Advances on Immune-Based Therapies for Patients with Hepatocellular Carcinoma
View More
Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
View More
2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers
View More
Community Practice Connections™: 19th Annual Meeting of the International Society of Gastrointestinal Oncology®
View More
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
View More
40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
MRD and Decision-Making in Early-Stage Colorectal Cancer
August 20th 2021This article reviews MRD and decision-making in early-stage colorectal cancer and includes insights from Christopher Lieu, MD, of the University of Colorado School of Medicine in Denver, and Daniel Ahn, DO, of the Mayo Clinic in Phoenix, AZ.
Examining Colon Cancer Outcomes in a Universal Health Care System Reveals High Survival Benefit
August 10th 2021United States Military Health System beneficiaries with colon cancer are more likely to have improved survival outcomes vs the general population, with a particularly notable benefit in Black patients.
Marwan G. Fakih, MD, Discusses Regorafenib Plus Nivolumab in CRC and Multidisciplinary Care
July 9th 2021CancerNetwork® sat down with Marwan G. Fakih, MD, of City of Hope at the 2021 ASCO Annual Meeting to talk about a potential multidisciplinary treatment approach to colorectal cancer with regorafenib/nivolumab.
Clinical Trials in Progress: COMMIT Study
July 4th 2021NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR/MSI-H Immunotherapy (COMMIT) Study: A Randomized Phase 3 Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination vs Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability–High (MSI-H) Metastatic Colorectal Cancer (NCT02997228).
Patients With Advanced CRC May Experience Survival Benefit With Lenvatinib Plus Pembrolizumab Combo
June 4th 2021Phase 2 data presented at the 2021 ASCO Annual Meeting indicate that more than half of patients with previously treated advanced colorectal cancer who were treated with pembrolizumab plus lenvatinib were alive at 6 months.
Andreana N. Holowatyj, PhD, MS, on Rising Rates of Early-Onset Colorectal Cancer Worldwide
April 30th 2021The lead author spoke about the rising incidence of early-onset colorectal cancer, which was the focal point of her research presented at the American Association for Cancer Research Annual Meeting 2021.
Complete Mesocolic Excision is a Safe Option in Laparoscopic Right Hemicolectomy
April 7th 2021Early safety data from the RELARC trial showed complete mesocolic excision doesn’t increase intraoperative and postoperative complications of laparoscopic right hemicolectomy compared with D2 dissection when done by an experienced surgeon.
KRAS Mutations in Unresectable Colorectal Liver Metastases Linked to Reduced Response Rates
March 18th 2021Based on a single-institution study, investigators were able to correlate outcomes for unresectable colorectal liver metastases with the addition of hepatic arterial infusion pump therapy to systemic therapy to the presence of a mutation in KRAS.